首页> 外文OA文献 >Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation

【2h】

Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation

机译：单克隆抗CD20抗体（rituximab）治疗大剂量化学疗法和自体造血细胞移植后复发性低度非霍奇金淋巴瘤的疗效和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Kaya Hakan; Keung Yi-Kong; Case Douglas; Cruz Julia M; Perry James J; Radford James E; Hurd David D;
展开▼
作者单位

展开▼
年度 2002
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 复发性晚期滤泡性淋巴瘤的IDEC-C2B8(利妥希玛)抗CD20抗体治疗:德国低度恶性淋巴瘤研究组Ⅱ期研究结果 [J] . 李登举, 唐锦治中德临床肿瘤学杂志（英文版） . 2001,第004期
2. Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation. [J] . Kaya H, Keung YK, Case D, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2002,第10期

机译：单克隆抗CD20抗体（rituximab）在大剂量化疗和自体造血细胞移植后治疗复发性低度非霍奇金淋巴瘤患者中的有效性和安全性。
3. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation. [J] . Tsai D, Moore H, Hardy C, Bone marrow transplantation . 1999,第5期

机译：利妥昔单抗（抗CD20单克隆抗体）治疗用于大剂量治疗和自体外周血干细胞移植后的进行性中度非霍奇金淋巴瘤。
4. Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study [J] . Di Renzo Nicola, Musso Maurizio, Scime Rosanna, Bone marrow transplantation . 2020,第11期

机译：多剂量Nepa的疗效和安全性没有地塞米松预防多日和高剂量化疗诱导的非Hodgkin淋巴瘤患者患者进行自体造血干细胞移植患者的恶心和呕吐：A相IIA，多中心研究
5. Clinical Outcome of Breast and Ovarian Cancer Patients Treated after High-Dose Chemotherapy and Autologous Stem Cell Rescue with Theratope (STn-KLH) Cancer Vaccine: Theratope (STn-KLH) Cancer Vaccine following Autologous Transplant [C] . Leona A. Holmberg, Katherine A. Guthrie, Brenda M. Sandmaier Chemical glycobiology . -1

机译：大剂量化学疗法和自体干细胞拯救治疗的Theratope（STn-KLH）癌症疫苗治疗的乳腺癌和卵巢癌患者的临床结果：自体移植后的Theratope（STn-KLH）癌症疫苗
6. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
7. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin’s lymphoma in patients 65 years of age [O] . C. Hosing, R. M. Saliba, G.-J. Okoroji, -1

机译：65岁以上患者的大剂量化疗和自体造血祖细胞移植治疗非霍奇金淋巴瘤
8. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy [O] . van der Kolk, L. E., Grillo-López, A. J., Baars, J. W., 2003

机译：嵌合抗CD20单克隆抗体（利妥昔单抗）和G-CSF联合治疗复发性B细胞非霍奇金淋巴瘤：关于安全性和有效性的最终报告

Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation

著录项

引文网络

相似文献

相关主题

期刊订阅